<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006219</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068084</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>979202</secondary_id>
    <nct_id>NCT00006219</nct_id>
  </id_info>
  <brief_title>Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma</brief_title>
  <official_title>A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be&#xD;
      effective in preventing multiple myeloma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone&#xD;
      with that of clarithromycin in treating patients who may be at a high risk of developing&#xD;
      multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether dehydroepiandrosterone (DHEA) or clarithromycin causes a significant&#xD;
           reduction in bone marrow plasmacytosis, serum and/or urine M protein or Bence Jones&#xD;
           protein, and surrogate endpoint biomarkers in patients with monoclonal gammopathy of&#xD;
           undetermined or borderline significance.&#xD;
&#xD;
        -  Determine whether differences in interleukin-1-beta (IL-1-beta) expression and IL-1-beta&#xD;
           dependent biomarkers (adhesion molecule expression and serum interleukin-6 levels) are&#xD;
           useful surrogate endpoint biomarkers in these patients.&#xD;
&#xD;
        -  Determine whether differences in ploidy, proliferative index, nuclear pleomorphism&#xD;
           index, circulating monoclonal plasma cells, Th1/Th2 ratios, serum s-interleukin-6R&#xD;
           (SIL-6R) levels, interleukin-6 and SIL-6R expression, or plasma cell apoptosis assay are&#xD;
           useful surrogate endpoint biomarkers in these patients.&#xD;
&#xD;
        -  Determine the effects of these treatment regimens on the quality of life of these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      stratified according to disease (monoclonal gammopathy of undetermined significance vs&#xD;
      monoclonal gammopathy of borderline significance) and monoclonal protein abnormality (IgG vs&#xD;
      IgA). Patients are randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral dehydroepiandrosterone (DHEA) once daily.&#xD;
&#xD;
        -  Arm II: Patients receive oral clarithromycin once or twice daily.&#xD;
&#xD;
        -  Arm III: Patients receive oral placebo once daily.&#xD;
&#xD;
        -  Arm IV: Patients receive oral placebo twice daily. Treatment continues for 6 months in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, 6 months, 12 months, and then at disease&#xD;
      progression.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months for 1.5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75 patients (25 per treatment arms I and II and 25 between arms&#xD;
      III and IV) will be accrued for this study within 2.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  New or prior diagnosis of 1 of the following:&#xD;
&#xD;
               -  Monoclonal gammopathy of undetermined significance&#xD;
&#xD;
                    -  Bone marrow plasma cells of less than 10%&#xD;
&#xD;
               -  Monoclonal gammopathy of borderline significance&#xD;
&#xD;
                    -  Bone marrow plasma cells of 10-30%&#xD;
&#xD;
          -  Serum IgG or IgA at least 1.5 g/dL&#xD;
&#xD;
          -  Bone marrow plasmacytosis no greater than 30%&#xD;
&#xD;
          -  No multiple myeloma, amyloidosis, or B-cell neoplasm&#xD;
&#xD;
          -  No evidence of bone lesions&#xD;
&#xD;
          -  Prostate-specific antigen less than 4 ng/mL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless history of&#xD;
             Gilbert's disease)&#xD;
&#xD;
          -  AST and ALT no greater than 1.5 times ULN (unless history of Gilbert's disease)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.8 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No prior thromboembolic event within the past 5 years&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prostate cancer or clinically significant benign prostatic hypertrophy&#xD;
&#xD;
          -  No prior malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No malignancy suspected on mammogram&#xD;
&#xD;
          -  No hypersensitivity to DHEA, clarithromycin, or any macrolide antibiotic (e.g.,&#xD;
             erythromycin)&#xD;
&#xD;
          -  No insulin-dependent diabetes&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier method of contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 30 days since prior DHEA or other steroids that may affect M protein&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since prior clarithromycin&#xD;
&#xD;
          -  At least 30 days since any other prior agents that may affect M protein&#xD;
&#xD;
          -  No concurrent cisapride, terfenadine, pimozide, astemizole, or loratadine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Lust, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 2, 2011</last_update_submitted>
  <last_update_submitted_qc>August 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>John A. Lust, M.D.</name_title>
    <organization>Mayo Clinic Cancer Center</organization>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

